Drugmakers in China Explore AI Marketing Amid Anti-Graft Scrutiny

Reuters reported on November 11, 2026 that pharmaceutical companies in China are exploring marketing through medical AI assistants and customized disease-specific academic platforms as stricter anti-corruption enforcement complicates traditional visits to doctors and hospitals.

The opportunities fall into two distinct categories. Null Hypothesis CEO Gu Fei said major Chinese and foreign drugmakers have licensed its KnowS product to build physician-facing academic platforms focused on particular diseases, although he declined to name them. Other ideas remain proposals: Alibaba Health is considering placing promoted research and clinical evidence beside relevant AI-generated answers on Hydrion, while drugmakers have discussed search prominence and academic endorsements with Yidu Tech, which is not yet offering those functions on Yidu Evidence.

Alibaba Health has not begun drugmaker collaborations on Hydrion, although chief technology officer Wang Xiangzhi described interest from domestic and foreign companies as strong. Roche said it explores third-party medical AI tools for direct marketing to doctors and hospitals, while Bayer said it monitors technology that could support compliant engagement with healthcare professionals.

Gu described a shift away from hospitality and gift-giving toward tools that support clinical work and research. From a doctor’s perspective, he said, “this really gives me a new capability and helps me improve efficiency, rather than you giving me two bottles of Moutai.”

Compliance Pressure Meets Rising AI Use

A multiyear campaign against healthcare bribery and corruption intensified in summer 2026, when authorities introduced stricter measures for pharmaceutical employees who provide product information to doctors and hospitals. Medlive’s August 28, 2026 interim results describe sustained enforcement and medical-representative rules as raising compliance requirements, with drugmakers reducing traditional promotion spending and increasing the budget share for digital academic marketing built around traceable clinical evidence.

Alibaba Health’s survey of hundreds of doctors found that 93% used AI tools, compared with about 70% a year earlier. The comparison indicates rapid adoption among physicians, but it measures AI tools broadly rather than usage of any one platform.

Frost & Sullivan estimates that Chinese enterprise spending on digital health marketing will grow at a 27.5% compound annual rate from 2027 to 2030, reaching RMB274.4 billion. Its projection covers the broader category and provides no separate figure for physician-facing AI applications.

Evidence Tools Offer the Distribution Channel

Alibaba Health’s Hydrion product page describes literature and guideline searches, drug-information lookup, AI question answering, PDF translation and summarization, and content collaborations with BMJ, JAMA and NEJM. The listed resources include 40 million papers, more than 30,000 guidelines and more than 60,000 drug instructions.

JD Health’s September 8, 2026 account of Zhiyi says the assistant launched in January 2026 and had served more than one million doctors and supported over 20 million clinical decision-making interactions. Its evidence-location feature identifies the original text supporting a clinical point, allowing physicians to trace generated information back to the underlying evidence.

JD Health formed its PICA Health partnership in August 2026, making Zhiyi available free to registered primary-care doctors through PICA’s app. PICA Health says AI-embedded content is limited to disease education, clinical guidelines and care standards, excludes branded drug recommendations and product-oriented content, and undergoes academic review. That policy draws a boundary between clinical education and brand-directed promotion on PICA’s platform, even as pharmaceutical companies seek access to the same physician workflow.

Activity Grows Faster Than Revenue

Medlive’s interim results show 217 healthcare customers for precision marketing and corporate solutions in the first half of 2026, up from 191 a year earlier, while marketed products rose from 445 to 509. Segment revenue increased 1.1% to RMB295.5 million.

The company attributed the gap between expanding activity and modest revenue growth to two pressures: stricter regulation disrupted physicians’ participation in online and offline academic activities and delayed some projects, while smaller pharmaceutical marketing budgets constrained near-term investment in digital academic marketing.

For now, KnowS licensing and Medlive’s customer growth show that parts of the shift are already commercial, while promoted evidence beside AI answers and preferred search placement remain proposals. The opportunity is tied to a compliance question: how platforms distinguish physician education and traceable clinical evidence from brand-directed promotion as drugmakers seek a larger presence in doctors’ daily workflows.